Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday, following reports that the company’s weight-loss drug, MariTide, triggers a significant loss in bone density. Last seen holding above $300, AMGN could be due for more chart recovery if past is precedent.Specifically, Amgen stock pulled back to within one standard deviation of its 320-day moving average during yesterday's negative price action. Per Schaeffer's Senior Quantitative Analyst ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.On Wednesday, Amgen Inc AMGN stated the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data, saying, “Amgen does not see an association between the administration of MariTide and bone mineral density (BMD) changes. The Phase 1 study results do not suggest any bone safety concerns or change our conviction in the promise of MariT ...

CHINA - 2024/09/17: In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo Illustration by Alvin Chan/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesAmgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone density, which could be a potential safety risk. MariTide is an important ...

THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data."As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data later this year."Amgen Forwar ...

Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to PlaceboTHOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and ...

Amgen (AMGN) reported third-quarter 2024 adjusted earnings of $5.58 per share, which beat the Zacks Consensus Estimate of $5.11. Earnings rose 13% year over year as higher revenues offset the impact of higher operating costs and interest expenses.Total revenues of $8.51 billion came in line with the Zacks Consensus Estimate. Total revenues rose 23% year over year.Total product revenues increased 24% from the year-ago quarter to $8.15 billion. Higher volumes were partially offset by lower selling prices of s ...

Amgen Inc. (NASDAQ:AMGN) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease) James Bradner - EVP, Research and Development & Chief Scientific Officer Peter Griffith - EVP & CFO Conference Call Participants Salveen Richter - Goldman Sachs Olivia Brayer - Cantor Fitzgerald ...

Q3 '24 Earnings Call October 30, 2024 Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of incorporation or organization)(I. ...

For the quarter ended September 2024, Amgen (AMGN) reported revenue of $8.5 billion, up 23.2% over the same period last year. EPS came in at $5.58, compared to $4.96 in the year-ago quarter.The reported revenue represents a surprise of -0.04% over the Zacks Consensus Estimate of $8.51 billion. With the consensus EPS estimate being $5.11, the EPS surprise was +9.20%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their nex ...